Genitourinary Cancers Symposium Annual Meeting Coverage

NSAIDs May Raise Risk of Fatal Kidney Cancer

NSAIDs May Raise Risk of Fatal Kidney Cancer

Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

The protective effect was not observed with other anti-diabetic medications.

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.

Healthy Lifestyle After PCa Diagnosis Beneficial

Healthy Lifestyle After PCa Diagnosis Beneficial

Through diet and exercise, prostate cancer patients can decrease their risk of dying from their illness.

Study: ADT, Radiotherapy Possibly Reduce Bladder Cancer Risk

Study: ADT, Radiotherapy Possibly Reduce Bladder Cancer Risk

The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.

Bladder Tumor Resection Key to Cystectomy Outcomes

Bladder Tumor Resection Key to Cystectomy Outcomes

Researchers estimate that 40% of pathologic response in MIBC patients receiving both neoadjuvant chemo and TURBT is due to TURBT.

Travel Distance to Provider Predicts Post-Cystectomy Readmission

Travel Distance to Provider Predicts Post-Cystectomy Readmission

A travel distance of more than 30 miles to the provider was associated with greater chances of readmission in one analysis.

Study: 5-ARIs Lower Prostate Cancer Progression Risk

Study: 5-ARIs Lower Prostate Cancer Progression Risk

Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs.

CTC Heterogeneity Predicts Hormone Therapy Response in mCRPC

CTC Heterogeneity Predicts Hormone Therapy Response in mCRPC

Patients with higher heterogeneity score did not respond well to hormone therapy.

Radium-223 Repeat Treatment Safe, Effective

Radium-223 Repeat Treatment Safe, Effective

Second round of 6 injections was well tolerated and continued to control disease progression in bone.

Early PSA Response to Abiraterone Predicts Better Outcomes

Early PSA Response to Abiraterone Predicts Better Outcomes

A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.

Statins May Prolong Abiraterone Treatment Duration

Statins May Prolong Abiraterone Treatment Duration

Researchers observed a trend toward longer time on drug among men with castration-resistant prostate cancer.

Cabozantinib Improves PFS in Patients With Advanced RCC

Cabozantinib Improves PFS in Patients With Advanced RCC

The drug nearly doubled the delay in tumor growth compared with everolimus.

Aspirin May Reduce Risk of Lethal Prostate Cancer

Aspirin May Reduce Risk of Lethal Prostate Cancer

In large observational study, regular use—defined as 3 tablets per week—was associated with a 24% lower risk of dying from prostate cancer.

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.

Sign Up for Free e-newsletters